Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing

• Charlotte L. B. M. Korst,
• Kaz Groen,
• Patricia W. C. Bosman,
• Fleur van derValk,
• Christie P. M. Verkleij,
• Sandy Kruyswijk,
• Maaike E. M. deRuijter,
• Dianne M. Heijink,
• Maria T. Kuipers,
• Sonja Zweegman,
• Niels W. C. J. van deDonk

Affiliations

Charlotte L. B. M. Korst

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Kaz Groen

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Patricia W. C. Bosman

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Fleur van derValk

Department of Hematology Onze Lieve Vrouwe Gasthuis Amsterdam The Netherlands

Christie P. M. Verkleij

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Sandy Kruyswijk

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Maaike E. M. deRuijter

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Dianne M. Heijink

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Maria T. Kuipers

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Sonja Zweegman

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Niels W. C. J. van deDonk

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands